Business Wire

SEKISUI-HOUSE

30.11.2021 15:02:59 CET | Business Wire | Press release

Share
Sekisui House, Ltd.: Working With Customers for 20 Years to Conserve Urban Biodiversity With the Gohon no ki Indigenous Landscaping Concept

Sekisui House, Ltd. (TOKYO:1928) has been pursuing the conservation of biodiversity since 2001 by creating green networks in urban residential districts under its Gohon no ki (“five trees”) indigenous landscaping concept. Together with the University of the Ryukyus1 , the company has analyzed the outcome of the Gohon no ki Project that it has implemented with 1 million customer households2 over the space of 20 years, and has designed the world’s first mechanism for quantitatively evaluating urban biodiversity. It has published this qualitative evaluation mechanism today as a nature-positive methodology for promoting the conservation of biodiversity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005350/en/

The Gohon no ki Project

Since the 1970s, incessant urban development has dramatically reduced the amount of habitat available for flora and fauna in our cities. Sekisui House launched its Gohon no ki Project in 2001 as an initiative to conserve biodiversity through the eco-friendly landscaping and greening of the gardens of its customers. Based on the concept of planting five locally native trees, three for birds and two for butterflies, the Gohon no ki Project proposes greening gardens and local communities with native tree species suited to the local climate and benevolent to birds, butterflies, and other local fauna. The project takes its lead from garden landscaping modeled on traditional Japanese satoyama (which translates roughly as “village woodland”).

In the 20 years from 2001 up to 2020, more than 17 million trees have been planted under the project. The company has also promoted urban greening throughout Japan by incorporating the Gohon no ki concept into its planning of green spaces in its condominium and community development initiatives.

Quantitative evaluation of biodiversity

Sekisui House has since 2019 been working with the Kubota Laboratory, Faculty of Science, University of the Ryukyus, and Think Nature Inc. to quantitatively evaluate the contribution of this network-type greening to urban biodiversity. Based on the Japan Biodiversity Mapping Project (J-BMP)3 managed and operated by Think Nature Inc., a company established by Professor Yasuhiro Kubota, the partners have analyzed the data on tree number, species, and location accumulated over the 20 years of the Sekisui House Gohon no ki Project to quantitatively evaluate the effectiveness of the project in conserving and restoring biodiversity.

This quantitative evaluation revealed the following benefits for biodiversity from planting native tree species in line with the Gohon no ki Project as opposed to planting conventional horticultural and exotic species in gardens in urban areas where biodiversity has declined significantly (Japan’s three major metropolitan areas).4

  • The number of native tree species in each region—the foundation of regional biodiversity—has increased tenfold.
  • The number of bird species that residential districts can attract has doubled.
  • The number of butterfly species that residential districts can attract has increased fivefold.
  • Biodiversity in the three metropolitan areas has recovered to 30% of the level of 1977 for which the first trustworthy biodiversity related data exists.

This is the world’s first mechanism for quantitatively evaluating urban biodiversity and its application to an actual case. The disclosure of numerical data enables biodiversity to be expressed in terms of financial value, thereby providing a means for visualizing private sector contribution to biodiversity.

Nature-positive methodology

In recent years, increasing efforts are being made to conserve biodiversity. In June of this year, the Taskforce on Nature-related Financial Disclosures (TNFD) was launched, and in October, the 15th Conference of the Parties to the Convention on Biological Diversity (COP15) was held. In Japan too, discussion has begun in earnest on other effective area-based conservation measures (OECMs) for enlisting the support of the private sector to drive urban greening.

In this societal context, Sekisui House is making its 20-year biodiversity conservation initiative available to the public as a nature-positive methodology. The Gohon no ki Project’s nature-positive methodology represents a means for expressing urban biodiversity. Sekisui House is making this methodology available to the general public with the aim of raising awareness and enabling its store of knowledge and expertise to be utilized by others to promote greening and contribute to the conservation of biodiversity.

Nature-positive methodology website
https://www.sekisuihouse.co.jp/gohon_sp/method/

Predicted benefits

Based on joint review of available data, Sekisui House and its partners set the number of tree, bird, and butterfly species, diversity index, and number of individual trees, birds, and butterflies in 1977 as 100%, and using 2000, the year before the Gohon no ki Project was launched, as the base year, simulated change up to 2070 in Japan’s three largest metropolitan areas (Kanto, Kinki and Chukyo) that have suffered the greatest decline in biodiversity. This simulation indicated that planting native tree species that are likely to benefit local fauna (the Gohon no ki concept) compared to 2000, the year before the launch of the Gohon no ki Project, would enable biodiversity to recover to 37.4% of 1977 levels by 2030 (target year for conservation of biodiversity internationally), 40.9% by 2050, and 41.9% by 2070.

If the Gohon no ki concept of planting native trees were applied to 30% of all newly constructed properties in Japan moving forward, urban biodiversity is predicted to rise to 84.6% of 1977 levels. Sekisui House believes that this indicates that if the private sector works with the general public, the decline in biodiversity can be reversed to achieve the goal of post-2020 biodiversity recovery that is the theme of COP15, and that its Gohon no ki concept can contribute to this goal.

We've received comments of endorsement from the following people. For more details, please refer to the attached document or the original news release via your browser.
https://www.sekisuihouse.co.jp/english/company/release/topics_2021/20211126_en/

  • Mr. Makoto Haraguchi, Fellow, MS & AD InterRisk Research Institute and Sustainability Section SVP for TNFD, MS & AD Insurance Group Holdings
  • Mr. Teppei Dohke, Executive Secretary General of the Japan Committee for the International Union for Conservation of Nature
  • Ms. Mariko Kawaguchi, Specially Appointed Professor, Rikkyo University / Executive Advisor to CEO, Fuji Oil Holdings Inc.
  • Mr. Yasuhiro Kubota, Professor, Faculty of Science, University of the Ryukyus / Representative Director, Think Nature Inc.

1. This is joint research with the Kubota Laboratory, Faculty of Science, University of the Ryukyus.
2. Cumulative number of households built from February 2001 to January 2021 is 1,001,977.
3. Japan Biodiversity Mapping Project (J-BMP) website: https://biodiversity-map.thinknature-japan.com
4. Comparison of continuing to plant conventional garden tree species with planting tree species in line with the Gohon no ki concept over the 20 years from 2001 to 2020

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye